+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Organ and tumor dosimetry of 177Lu-DOTA-Tyr3-octreotate and 90Y-DOTA-Tyr3-octreotide A preliminary study in 2 patients



Organ and tumor dosimetry of 177Lu-DOTA-Tyr3-octreotate and 90Y-DOTA-Tyr3-octreotide A preliminary study in 2 patients



Journal of Nuclear Medicine 43(5 Suppl.): 316P




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035436423

Download citation: RISBibTeXText


Related references

Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia. Nuclear Medicine and Biology 41(1): 36-42, 2014

Bone marrow dose results in peptide receptor radionuclide therapy with 90Y-DOTA-Tyr3-Octreotide, 111In-DTPA-Octreotide and 177Lu-DOTA-Octreotate Importance of dosimetry model. Journal of Nuclear Medicine 43(5 Suppl.): 90P, 2002

Rapid and high-yield solution-phase synthesis of DOTA-Tyr3-octreotide and DOTA-Tyr3-octreotate using unprotected DOTA. Tetrahedron Letters 44(11): 2393-2396, 10 March, 2003

Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer BioTherapy and Radiopharmaceuticals 20(2): 231-236, 2005

Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate. Anticancer Research 27(6b): 3941-3946, 2008

Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer BioTherapy and Radiopharmaceuticals 23(1): 114-120, 2008

Treatment with 177Lu-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors. Journal of Nuclear Medicine 43(5 Suppl.): 34P, 2002

Hypocalcaemia after treatment with [177Lu-DOTA 0,Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging 40(12): 1843-1852, 2013

Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 33(5): 532-540, 2006

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging 30(3): 417-422, 2003

177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. International Journal of Cancer 92(5): 628-633, 2001

Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro. Cancer BioTherapy and Radiopharmaceuticals 18(5): 761-768, 2003

2269 [177Lu-Dota]-D-Phe1-Tyr3-octreotide (177Lu-Dotatoc) for peptide receptor radiotherapy in patients with advanced neuroendocrine tumours: A retrospective phase Ii study of efficacy and safety. European Journal of Cancer 51: S422-S423, 2015

Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model. Journal of Nuclear Medicine 45(9): 1542-1548, 2004

Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal. Endocrine Practice 14(2): 213-218, 2008